ADAPT 2.0 Approach With Imperative Care’s Zoom System Evaluated to Treat Ischemic Stroke 

November 24, 2025—Imperative Care, Inc. announced late-breaking, real-world data from a multicenter review of 124 consecutive ischemic stroke patients treated with the ADAPT 2.0 approach using the company’s Zoom stroke system for mechanical thrombectomy between April 2025 and September 2025.

ADAPT 2.0—the next-generation of the ADAPT (a direct aspiration first-pass technique) approach—combines 0.088-inch intracranial access, asymmetric aspiration, and the continuous dual aspiration technique (CDAT) for clot removal, stated the company.

The findings were presented by Max Mokin, MD, at SVIN 2025, the Society of Vascular and Interventional Neurology annual meeting.

According to Imperative Care, the most frequent occlusion site reported in patients was the M1 segment of the middle cerebral artery (48%, 59/124), followed by the M2 segment (24%, 30/124).

As summarized in the company’s press release, the review data demonstrated a 97% rate of final modified thrombolysis in cerebral infarction (mTICI) ≥ 2b (120/124) and an 80% rate of final mTICI ≥ 2c (99/124). The median procedure time was 17 minutes with a median of one pass per procedure. There was a 98% rate of full clot ingestion and capture in one or both Zoom peripheral occlusion devices (PODs) (111/113) and an outer Zoom 88 POD captured clot in 35% of cases (40/113).

“In addition to the 17-minute median procedure time and the minimal number of passes per procedure, we saw a 98% rate of full clot ingestion in this cohort, meaning the entire clot was successfully captured in one or both Zoom PODs,” commented Dr. Mokin in Imperative Care’s press release.

Dr. Mokin continued, “Clot was observed in the Zoom 88 POD in 35% of all cases, which may have otherwise been lost without continuous dual aspiration on the inner and outer catheters. This underscores a key potential benefit of ADAPT 2.0, providing physicians with greater control and confidence during stroke procedures by reducing the risk of clot loss and offering immediate visual feedback of clot capture. I look forward to future larger studies to further elucidate the clinical benefits of CDAT and ADAPT 2.0 for stroke patients.”